STAAR Surgical Company (NASDAQ:STAA) manufacturer of eye care devices, is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.03 per share.
For the full year, analysts predict revenues of $ 156.24 million, while looking forward to income of $ 0.05 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 177.20 million ~ $ 177.20 million
Click Here For More Historical Outlooks Of STAAR Surgical Company
Previous Quarter Performance
STAAR Surgical Company communicated income for the second quarter of $ 0.03 per share, from the revenue of $ 35.19 million. Wall street analysts are predicting, STAA to report 2Q20 loss of $ 0.04 per share from revenue of $ 35.75 million. The bottom line results beat street analysts by $ 0.07 or 175.00 percent, at the same time, top line results fell short of analysts by $ 0.56 million or 1.57 percent.
Stock Performance
Shares of STAAR Surgical Company traded low $ -1.32 or -1.83 percent on Tuesday, reaching $ 70.44 with volume of 537.40 thousand shares. STAAR Surgical Company has traded high as $ 73.43 and has cracked $ 70.30 on the downward trend
According to the previous trading day, closing price of $ 70.44, representing a 209.31 % increase from the 52 week low of $ 23.20 and a 4.63 % decrease over the 52 week high of $ 75.24.
The company has a market capital of $ 3.23 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
STAAR Surgical Company will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.staar.com
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery.
